MK-677 common uses, half-life, side effects and more

MK-677 is an orally active drug that makes the pituitary release its own growth hormone. It is a small molecule rather than a peptide. It is swallowed rather than injected. People take it for muscle gain, appetite, sleep, and recovery. It has never been approved for any use in any country. It reached large trials for Alzheimer's disease, hip fracture recovery, and osteoporosis. None of them led to approval. The molecule is still in development for growth hormone deficiency in children. It is sold online as a research chemical and cannot lawfully be sold as a supplement. It also turns up undeclared in products sold as something else.

• Raising growth hormone and IGF-1 without injecting growth hormone itself
• Muscle gain and body composition
• Appetite support when eating above maintenance
• Deeper sleep
• Historical testing for frailty, hip fracture recovery, and Alzheimer's disease

Once daily

Clinical trials used 25 mg by mouth once daily. That dose appears in almost every adult study. Community practice runs wider and sits lower. First-hand reports span roughly 5 to 30 mg a day. A common pattern is starting at 25 mg, finding the tiredness unmanageable, and settling at 12.5 mg. People adjust in both directions rather than following a fixed schedule. The growth hormone response rose with dose from 2 mg to 25 mg in healthy older adults. No trial has properly compared doses above 25 mg.

• Most people take it at bedtime so they sleep through the tiredness and the appetite peak
• A daily dose keeps IGF-1 raised around the clock so timing changes when the acute effects land rather than the hormonal result
• Sold as capsules and as an oral liquid that users widely report tastes bad and is harder to dose accurately
• Community practice on duration runs from continuous use to deliberate on and off blocks

No human study has ever measured how long MK-677 itself lasts in the blood. The widely quoted 4.7 hours is a dog value and its own source says so. A separate 6 hour figure traces to a book review rather than to any study of the drug. What is established is the effect rather than the drug level. A single daily dose keeps growth hormone and IGF-1 raised across a full 24 hours.

• Increased appetite is the most reliable effect and it eased within three months for about half of the people who got it
• Raised fasting glucose and HbA1c with falling insulin sensitivity is the most consistent finding in the whole trial record
• Fluid retention and mild swelling of the lower legs at rates that ran from 4 to 44 percent across trials
• Tiredness that people report far more often than the trials recorded
• Muscle pain affected a third of people on the drug against under a tenth on placebo
• Numbness or tingling in the hands is common in user reports and tends to worsen rather than settle

MK-677 activates the ghrelin receptor and makes the pituitary release its own growth hormone. That raises IGF-1 from the liver. It acts on the pituitary and the hypothalamus at once. It increases growth hormone releasing hormone, strengthens that hormone's effect on the pituitary, and lowers the somatostatin that brakes growth hormone release. The same receptor drives hunger so appetite rises alongside. How much growth hormone rises depends on how much room the axis has. Two weeks of dosing raised 24 hour growth hormone by about 97 percent in healthy older adults. One week did not raise total growth hormone output in healthy young men. IGF-1 still rose with dose in those same men. Researchers used this compound as the probe to clone the receptor in 1996 and did not identify ghrelin as the body's own activator until three years later.

MK-677 has a real clinical trial record. The largest study randomized 563 people with Alzheimer's disease to a year of treatment and found no effect on any cognitive or functional measure. A two year study in healthy older adults added about a kilogram of lean mass at twelve months and produced no gain in strength and no gain in physical function. A hip fracture trial was stopped early over a heart failure signal and its authors concluded that the risk and the benefit did not balance for that group. An osteoporosis trial and an earlier hip fracture trial both missed their main endpoints. The compound reliably raises growth hormone and IGF-1. No trial has shown that this turns into a health or performance benefit. Its behavior in the human body is almost undescribed. No carcinogenicity, genotoxicity, or repeat dose toxicity study has ever been published.

• A hip fracture trial in frail older adults was stopped early after four people on the drug developed heart failure against one on placebo
• Blood pressure rose on treatment in that same trial and stayed raised from the fourth week onward
• It raises blood sugar and lowers insulin sensitivity in nearly every study that has measured them
• A normal fasting glucose does not rule that effect out because one trial found normal fasting values alongside an impaired glucose tolerance test
• Growth hormone and IGF-1 drive cell growth so it is not for anyone with a current or past cancer
• No pregnancy or breastfeeding data exist for this compound in any species